✦ LIBER ✦

A phase I/II study of S-1 plus cisplatin in patients with advanced gastric cancer: 2-week S-1 administration regimen

✍ Scribed by Yasuhiro Sato; Hitoshi Kondo; Kana Honda; Daisuke Takahari; Tetsuya Sumiyoshi; Yasushi Tsuji; Naohito Yoshizaki; Yoshiro Niitsu

Publisher: Springer
Year: 2005
Tongue: English
Weight: 208 KB
Volume: 10
Category: Article
ISSN: 1341-9625
DOI: 10.1007/s10147-004-0451-z

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Multicenter phase II study of weekly pac

Multicenter phase II study of weekly paclitaxel plus S-1 combination chemotherapy in patients with advanced gastric cancer

✍ Yuji Ueda; Hisakazu Yamagishi; Daisuke Ichikawa; Kazuma Okamoto; Eigo Otsuji; Ju 📂 Article 📅 2010 🏛 Springer 🌐 English ⚖ 210 KB

Phase I study of cediranib in combinatio

Phase I study of cediranib in combination with cisplatin plus fluoropyrimidine (S-1 or capecitabine) in Japanese patients with previously untreated advanced gastric cancer

✍ Taroh Satoh; Yasuhide Yamada; Kei Muro; Hidetoshi Hayashi; Yasuhiro Shimada; Dai 📂 Article 📅 2011 🏛 Springer 🌐 English ⚖ 241 KB

A phase I combination chemotherapy study

A phase I combination chemotherapy study of biweekly paclitaxel and S-1 administration in patients with advanced gastric cancer

✍ Shuichi Hokita; Takashi Aikou; Futoshi Miyazono; Sumiya Ishigami; Kuniaki Aridom 📂 Article 📅 2005 🏛 Springer 🌐 English ⚖ 201 KB

Performance of outpatient regimen of S-1

Performance of outpatient regimen of S-1 in combination with fractional cisplatin for advanced or recurrent gastric cancers: a phase I study

✍ Shouji Shimoyama; Kazuhiro Imamura; Naoki Hiki; Hirokazu Yamaguchi; Ken-ichi Maf 📂 Article 📅 2005 🏛 Springer 🌐 English ⚖ 206 KB

Extended safety and efficacy data on S-1

Extended safety and efficacy data on S-1 plus cisplatin in patients with untreated, advanced gastric carcinoma in a multicenter phase II study

✍ Heinz-Joseph Lenz; Fa-Chyi Lee; Daniel G. Haller; Deepti Singh; Al B. Benson III 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 217 KB

## Abstract ## BACKGROUND. S‐1 is a promising oral fluoropyrimidine. The authors obtained extended Phase II safety and efficacy data in a multicenter setting for the S‐1 plus cisplatin combination: The experimental arm of the global Phase III First‐Line Advanced Gastric Cancer Study (FLAGS) is bei

Phase I/II study of 3-week combination o

Phase I/II study of 3-week combination of S-1 and cisplatin chemotherapy for metastatic or recurrent gastric cancer

✍ Jae-Lyun Lee; Hye Jin Kang; Yoon-Koo Kang; Min-Hee Ryu; Heung Moon Chang; Tae-Wo 📂 Article 📅 2007 🏛 Springer 🌐 English ⚖ 420 KB